Of Screening, Stratification, and Scores
暂无分享,去创建一个
[1] B. Knoppers,et al. Biomedical Data Identifiability in Canada and the European Union: From Risk Qualification to Risk Quantification? , 2021, SCRIPT-ed.
[2] Jennifer D. Brooks,et al. Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I) , 2021, Journal of personalized medicine.
[3] B. Køster. Reduced cancer risk from healthier lifestyle , 2021, Acta oncologica.
[4] R. Houlston,et al. Will polygenic risk scores for cancer ever be clinically useful? , 2021, npj Precision Oncology.
[5] P. Donnelly,et al. Validation of an Integrated Risk Tool, Including Polygenic Risk Score, for Atherosclerotic Cardiovascular Disease in Multiple Ethnicities and Ancestries. , 2021, The American journal of cardiology.
[6] Xiaoping Zhou,et al. On cross-ancestry cancer polygenic risk scores , 2021, medRxiv.
[7] Jennifer D. Brooks,et al. Women’s Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada , 2021, Journal of personalized medicine.
[8] Paul J. Harrison,et al. Ethical Issues in Consent for the Reuse of Data in Health Data Platforms , 2021, Science and Engineering Ethics.
[9] Alicia R. Martin,et al. Leveraging fine-mapping and non-European training data to improve trans-ethnic polygenic risk scores , 2021, medRxiv.
[10] D. Easton,et al. CanRisk Tool—A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants , 2020, Cancer Epidemiology, Biomarkers & Prevention.
[11] A. Price,et al. Improving the trans-ancestry portability of polygenic risk scores by prioritizing variants in predicted cell-type-specific regulatory elements , 2020, Nature Genetics.
[12] J. Kaye,et al. Governance of research consortia: challenges of implementing Responsible Research and Innovation within Europe , 2020, Life Sciences, Society and Policy.
[13] Mark Barnes,et al. How to fix the GDPR's frustration of global biomedical research , 2020, Science.
[14] Jessica L Roberts,et al. GENETIC DUTIES. , 2020, William and Mary law review.
[15] Jeroen J. van den Broek,et al. Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History , 2020, Journal of the National Cancer Institute.
[16] Jingmei Li,et al. European polygenic risk score for prediction of breast cancer shows similar performance in Asian women , 2020, Nature Communications.
[17] L. Esserman,et al. Personalized early detection and prevention of breast cancer: ENVISION consensus statement , 2020, Nature Reviews Clinical Oncology.
[18] O. Topolcan,et al. Biobanks in the era of big data: objectives, challenges, perspectives, and innovations for predictive, preventive, and personalised medicine , 2020, EPMA Journal.
[19] E. Vassos,et al. Polygenic risk scores: from research tools to clinical instruments , 2020, Genome Medicine.
[20] R. Manchanda,et al. Population-based Genetic Testing for Precision Prevention , 2020, Cancer Prevention Research.
[21] P. Pharoah,et al. The challenge of early detection in cancer , 2020, Science.
[22] L. Susswein,et al. Ancestry-specific hereditary cancer panel yields: Moving toward more personalized risk assessment. , 2020, Journal of genetic counseling.
[23] B. Meiser,et al. Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field , 2020, Breast Cancer Research.
[24] H. Torun,et al. A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification , 2019, Hormones and Cancer.
[25] P. van Baal,et al. Cost-Effectiveness of Cancer Screening: Health and Costs in Life Years Gained. , 2019, American journal of preventive medicine.
[26] R. Eeles,et al. Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study , 2019, PLoS medicine.
[27] S. Duffy,et al. Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines , 2019, Annals of Internal Medicine.
[28] B. Knoppers,et al. A Legal Duty of Genetic Recontact in Canada , 2019 .
[29] M. Khoury,et al. Perspective: The Clinical Use of Polygenic Risk Scores: Race, Ethnicity, and Health Disparities. , 2019, Ethnicity & disease.
[30] Rachel L. Ross,et al. Implementing Risk Stratification in Primary Care: Challenges and Strategies , 2019, The Journal of the American Board of Family Medicine.
[31] W. V. van Harten,et al. A duty to recontact in genetics: context matters , 2019, Nature reviews genetics.
[32] X. Castells,et al. A systematic review and quality assessment of individualised breast cancer risk prediction models , 2019, British Journal of Cancer.
[33] R. Tuttle,et al. Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up. , 2019, The Journal of clinical endocrinology and metabolism.
[34] E. Ziv,et al. A response to “Personalised medicine and population health: breast and ovarian cancer” , 2019, Human Genetics.
[35] L. Hindorff,et al. Defining and Achieving Health Equity in Genomic Medicine. , 2019, Ethnicity & disease.
[36] C. Alfano,et al. Personalized Risk-Stratified Cancer Follow-Up Care: Its Potential for Healthier Survivors, Happier Clinicians, and Lower Costs. , 2019, Journal of the National Cancer Institute.
[37] M. García-Closas,et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors , 2019, Genetics in Medicine.
[38] W. Harten,et al. A Duty to Recontact in the Context of Genetics: Futuristic or Realistic? , 2018, European Journal of Health Law.
[39] Paul Quinn,et al. Big genetic data and its big data protection challenges , 2018, Comput. Law Secur. Rev..
[40] S. Manley,et al. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing , 2018, JAMA.
[41] Timothy Shin Heng Mak,et al. Tutorial: a guide to performing polygenic risk score analyses , 2018, bioRxiv.
[42] W. Willett,et al. Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case–control study , 2018, PLoS medicine.
[43] E. Spackman,et al. Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis , 2018, Public Health Reviews.
[44] P. Pharoah,et al. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer , 2018, JAMA oncology.
[45] Vence L Bonham,et al. The Clinical Imperative for Inclusivity: Race, Ethnicity, and Ancestry (REA) in Genomics , 2018, bioRxiv.
[46] D. Curtis. Polygenic risk score for schizophrenia is more strongly associated with ancestry than with schizophrenia , 2018, bioRxiv.
[47] P. Marshall,et al. Including all voices in international data-sharing governance , 2018, Human Genomics.
[48] I. Cohen. Is There a Duty to Share Healthcare Data , 2018 .
[49] Andrew E. Teschendorff,et al. Epigenome-based cancer risk prediction: rationale, opportunities and challenges , 2018, Nature Reviews Clinical Oncology.
[50] T. Dent,et al. Risk stratification, genomic data and the law , 2018, Journal of Community Genetics.
[51] Urs Gasser,et al. Big Data, Health Law, and Bioethics , 2018 .
[52] S. Hill. Introducing genomics into cancer care , 2018, The British journal of surgery.
[53] Rachel L. Ross,et al. Perceptions of Risk Stratification Workflows in Primary Care , 2017, Healthcare.
[54] Ewan Birney,et al. Genomics in healthcare: GA4GH looks to 2022 , 2017, bioRxiv.
[55] Stephen Armstrong. Data, data everywhere: the challenges of personalised medicine , 2017, British Medical Journal.
[56] S. Schicktanz,et al. Why take part in personalised cancer research? Patients’ genetic misconception, genetic responsibility and incomprehension of stratification—an empirical‐ethical examination , 2017, European journal of cancer care.
[57] E. Álava,et al. Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH , 2017, Clinical and Translational Oncology.
[58] Tal Z. Zarsky,et al. Incompatible: The GDPR in the Age of Big Data , 2017 .
[59] A. Clarke,et al. Recontacting in clinical practice: the views and expectations of patients in the United Kingdom , 2017, European Journal of Human Genetics.
[60] B. Karlan,et al. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? , 2017, Gynecologic oncology.
[61] Victor Osamor,et al. Development of Bioinformatics Infrastructure for Genomics Research. , 2017, Global heart.
[62] M. Sekerija,et al. Cancer screening: policy recommendations on governance, organization and evaluation of cancer screening , 2017 .
[63] G. Lippi,et al. BRCA population screening for predicting breast cancer: for or against? , 2017, Annals of translational medicine.
[64] J. Struijs,et al. Defining Population Health Management: A Scoping Review of the Literature. , 2017, Population health management.
[65] R. Wolff,et al. The Interaction between Genetic Ancestry and Breast Cancer Risk Factors among Hispanic Women: The Breast Cancer Health Disparities Study , 2016, Cancer Epidemiology, Biomarkers & Prevention.
[66] G. V. Van Norman. Drugs and Devices , 2016, JACC. Basic to translational science.
[67] L. Klotz,et al. Active Surveillance for Intermediate Risk Prostate Cancer , 2016, Prostate Cancer and Prostatic Diseases.
[68] Annelien L Bredenoord,et al. Big Data in medical research and EU data protection law: challenges to the consent or anonymise approach , 2015, European Journal of Human Genetics.
[69] S. Grosse. Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis , 2015, Healthcare.
[70] M. Blute,et al. Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years. , 2015, Urologic oncology.
[71] S. Duffy,et al. Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC , 2015, British Journal of Cancer.
[72] Jane E. Carpenter,et al. Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants , 2015, JNCI Journal of the National Cancer Institute.
[73] A. Price,et al. Explicit modeling of ancestry improves polygenic risk scores and BLUP prediction , 2014, bioRxiv.
[74] S. Duffy,et al. Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis , 2014, Genetics in Medicine.
[75] B. Knoppers,et al. The ethical framing of personalized medicine , 2014, Current opinion in allergy and clinical immunology.
[76] M. Piccart,et al. Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[77] Aaron S Kesselheim,et al. FDA regulation of mobile health technologies. , 2014, The New England journal of medicine.
[78] D. Easton,et al. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface , 2013, British Journal of Cancer.
[79] F. Carinci,et al. Health research and systems’ governance are at risk: should the right to data protection override health? , 2013, Journal of Medical Ethics.
[80] C. Catton,et al. The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[81] D G Altman,et al. The benefits and harms of breast cancer screening: an independent review , 2013, British Journal of Cancer.
[82] D. Altman,et al. The benefits and harms of breast cancer screening: an independent review , 2012, The Lancet.
[83] Stephen T Holgate,et al. The future of technologies for personalised medicine. , 2012, New biotechnology.
[84] M. Verma. Personalized Medicine and Cancer , 2012, Journal of personalized medicine.
[85] Kensaku Kawamoto,et al. Bmc Medical Informatics and Decision Making a National Clinical Decision Support Infrastructure to Enable the Widespread and Consistent Practice of Genomic and Personalized Medicine , 2009 .
[86] A. Andermann,et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. , 2008, Bulletin of the World Health Organization.
[87] J. Gray,et al. Maximising benefit and minimising harm of screening , 2008, BMJ : British Medical Journal.
[88] Larry J. Brindza,et al. What is a premarket notification 510(k) , 1980 .
[89] M. Zavon. Principles and Practice of Screening for Disease. , 1969 .
[90] Patricia A. H. Williams,et al. Software as a Medical Device (SaMD): Useful or Useless Term? , 2021, HICSS.
[91] Alicia R. Martin,et al. Leveraging fine-mapping and non-European training data to improve cross-population polygenic risk scores , 2021 .
[92] John W. Loonsk,et al. A proposed national research and development agenda for population health informatics: summary recommendations from a national expert workshop , 2017, J. Am. Medical Informatics Assoc..
[93] S. Narod,et al. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy , 2017, Breast Cancer Research and Treatment.
[94] M. Roobol,et al. Risk stratification in prostate cancer screening , 2013, Nature Reviews Urology.
[95] L. Klotz. Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention , 2008, Nature Clinical Practice Urology.
[96] L. Katz,et al. Medical devices. , 1985, Dimensions in health service.
[97] Data saves lives: reshaping health and social care with data , 2022 .